

Paul Eliezer Oberstein

List of Publications by Citations

Source: <https://exaly.com/author-pdf/439623/paul-eliezer-oberstein-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

33
papers

2,350
citations

14
h-index

37
g-index

37
ext. papers

2,961
ext. citations

6.9
avg, IF

4.61
L-index

#	Paper	IF	Citations
33	Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. <i>Cancer Cell</i> , 2014 , 25, 735-47	24.3	1235
32	HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 359-366	2.2	248
31	Pancreatic cancer: why is it so hard to treat?. <i>Therapeutic Advances in Gastroenterology</i> , 2013 , 6, 321-37	4.7	193
30	Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study). <i>Clinical Cancer Research</i> , 2019 , 25, 5493-5502	12.9	99
29	Randomized Phase III Trial of Pegvorhialuronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3185-3194	2.2	92
28	Current and Emerging Therapies in Metastatic Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 1670-1678	16.84	84
27	Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes. <i>Gut</i> , 2019 , 68, 1034-1043	19.2	84
26	Cholinergic Signaling via Muscarinic Receptors Directly and Indirectly Suppresses Pancreatic Tumorigenesis and Cancer Stemness. <i>Cancer Discovery</i> , 2018 , 8, 1458-1473	24.4	83
25	Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer. <i>Oncotarget</i> , 2017 , 8, 44073-44081	3.3	45
24	Results from a phase 2b, randomized, multicenter study of GVAX pancreas and CRS-207 compared to chemotherapy in adults with previously-treated metastatic pancreatic adenocarcinoma (ECLIPSE Study).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 345-345	2.2	33
23	Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours. <i>Neuroendocrinology</i> , 2018 , 107, 237-245	5.6	32
22	Uptake and patterns of use of gemcitabine for metastatic pancreatic cancer: a population-based study. <i>Cancer Investigation</i> , 2013 , 31, 316-22	2.1	16
21	Safety and efficacy of everolimus in adult patients with neuroendocrine tumors. <i>Clinical Medicine Insights: Oncology</i> , 2012 , 6, 41-51	1.8	15
20	Noninvasive Young® modulus visualization of fibrosis progression and delineation of pancreatic ductal adenocarcinoma (PDAC) tumors using Harmonic Motion Elastography (HME). <i>Theranostics</i> , 2020 , 10, 4614-4626	12.1	12
19	Harmonic Motion Imaging of Pancreatic Tumor Stiffness Indicates Disease State and Treatment Response. <i>Clinical Cancer Research</i> , 2020 , 26, 1297-1308	12.9	11
18	Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial. <i>Clinical Cancer Research</i> , 2021 , 27, 5020-5027	12.9	8
17	Metastatic gastric large cell neuroendocrine carcinoma: a case report and review of literature. <i>Clinical Colorectal Cancer</i> , 2012 , 11, 218-23	3.8	5

16	The efficacy and safety of sunitinib in patients with advanced well-differentiated pancreatic neuroendocrine tumors.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 380-380	2.2	5
15	Pancreatic neuroendocrine tumors: entering a new era. <i>JOP: Journal of the Pancreas</i> , 2012 , 13, 169-73	1.2	5
14	Moving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation. <i>JCO Oncology Practice</i> , 2021 , 17, 607-614	2.3	4
13	Novel agents in the treatment of unresectable neuroendocrine tumors. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. <i>JOP: Journal of the Pancreas</i> , 2011 , 12, 358-61	1.2	4
12	Reply to R-ST5, L-ST5 and KRJ-I are not authentic GEPNET cell lines <i>Nature Genetics</i> , 2019 , 51, 1427-1428	2.3	3
11	Unbiased Assessment of H-ST5 cells as high-fidelity models for gastro-enteropancreatic neuroendocrine tumor drug mechanism of action analysis		3
10	Update on novel therapies for pancreatic neuroendocrine tumors. <i>JOP: Journal of the Pancreas</i> , 2012 , 13, 372-5	1.2	3
9	Update on prognostic and predictive biomarkers for pancreatic neuroendocrine tumors. <i>JOP: Journal of the Pancreas</i> , 2012 , 13, 368-71	1.2	3
8	The Achilles Heel of Pancreatic Cancer: Targeting pancreatic cancer's unique immunologic characteristics and metabolic dependencies in clinical trials. <i>Journal of Pancreatology</i> , 2020 , 3, 121-131	1.9	2
7	Prospective phase II trial of GTX in metastatic pancreatic cancer: Laboratory and clinical studies.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 209-209	2.2	1
6	Transcriptional deconvolution reveals consistent functional subtypes of pancreatic cancer epithelium and stroma		1
5	A phase II study of chemotherapy and immune checkpoint blockade with pembrolizumab in the perioperative and maintenance treatment of locoregional gastric or GE junction adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS197-TPS197	2.2	0
4	The efficacy and safety of the capecitabine/temozolomide (CAPTEM) regimen in the treatment of well-differentiated neuroendocrine tumors with liver metastasis after failure of previous therapy: Columbia University Medical Center experience.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 308-308	2.2	0
3	Phase II open-label, single-center study evaluating safety and efficacy of pembrolizumab following induction with the hypomethylating agent azacitidine in patients with advanced pancreatic cancer after failure of first-line therapy.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS534-TPS534	2.2	
2	Gastric cancer prevention and early detection program for an at-risk population: A prospective study of the Korean American community.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 42-42	2.2	
1	Uptake and patterns of use of gemcitabine for stage IV pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e15074-e15074	2.2	